Cardiovascular patients take acetylsalicylic acid (ASA) for preventing myocardial infarction and other thromboembolic complications. It is already known that in some patients this therapy is not effective. The aim of this study was to assess the percentage of ASA resistance on the sample of patients with coronary artery bypass grafting. Our study included 105 patients with coronary artery bypass grafting treated with ASA 150 mg/day or lesser. Platelet aggregation was measured by serum thromboxane B2 level as well as impedance aggregometry from whole blood to determine ASA antiaggregation effect. The percentage of ASA resistance was 41.9% with impedance aggregometry, and after determining the serum thromboxane B2 level this percentage was only 8.6%. The correlation between these two methods was weak (r = 0.443; P < 0.0001). Thromboembolic complications still occur in ASA-treated patients because some patients are resistant to ASA therapy. It would be useful to monitor the effectiveness of ASA therapy and give another antiaggregation drug to these patients to reduce adverse events. The problem is which test is ideal because different tests show different percentages of ASA resistance.

Medical Biochemistry Laboratory Special Hospital for Medical Rehabilitation Krapinske Toplice Krapinske ToplicebDepartment of Cardiology Special Hospital for Medical Rehabilitation Krapinske Toplice Faculty of Medicine Osijek J J Strossmayer University of Osijek Osijek Croatiac2nd Department of Internal Medicine Comenius University and University Hospital Bratislava SlovakiadInternational Clinical Research Center St Anne's University Hospital and Masaryk University Brno Czech Republic*Ludovit Gaspar and Peter Kruzliak contributed equally to the writing of this article

000      

00000naa a2200000 a 4500

001      

bmc17014222

003      

CZ-PrNML

005      

20170502100526.0

007      

ta

008      

170413s2016 enk f 000 0|eng||

009      

AR

024    7_

$a 10.1097/MBC.0000000000000438 $2 doi

035    __

$a (PubMed)26575493

040    __

$a ABA008 $b cze $d ABA008 $e AACR2

041    0_

$a eng

044    __

$a enk

100    1_

$a Klasic, Anita $u aMedical Biochemistry Laboratory, Special Hospital for Medical Rehabilitation Krapinske, Toplice, Krapinske ToplicebDepartment of Cardiology, Special Hospital for Medical Rehabilitation Krapinske Toplice, Faculty of Medicine Osijek, J. J. Strossmayer University of Osijek, Osijek, Croatiac2nd Department of Internal Medicine, Comenius University and University Hospital, Bratislava, SlovakiadInternational Clinical Research Center, St. Anne's University Hospital and Masaryk University, Brno, Czech Republic*Ludovit Gaspar and Peter Kruzliak contributed equally to the writing of this article.

245    14

$a The monitoring of antiaggregation effect of acetylsalicylic acid therapy by measuring serum thromboxane B2 in patients with coronary artery bypass grafting / $c A. Klasic, N. Lakusic, L. Gaspar, P. Kruzliak,

520    9_

$a Cardiovascular patients take acetylsalicylic acid (ASA) for preventing myocardial infarction and other thromboembolic complications. It is already known that in some patients this therapy is not effective. The aim of this study was to assess the percentage of ASA resistance on the sample of patients with coronary artery bypass grafting. Our study included 105 patients with coronary artery bypass grafting treated with ASA 150 mg/day or lesser. Platelet aggregation was measured by serum thromboxane B2 level as well as impedance aggregometry from whole blood to determine ASA antiaggregation effect. The percentage of ASA resistance was 41.9% with impedance aggregometry, and after determining the serum thromboxane B2 level this percentage was only 8.6%. The correlation between these two methods was weak (r = 0.443; P < 0.0001). Thromboembolic complications still occur in ASA-treated patients because some patients are resistant to ASA therapy. It would be useful to monitor the effectiveness of ASA therapy and give another antiaggregation drug to these patients to reduce adverse events. The problem is which test is ideal because different tests show different percentages of ASA resistance.

650    _2

$a dospělí $7 D000328

650    _2

$a senioři $7 D000368

650    _2

$a senioři nad 80 let $7 D000369

650    _2

$a Aspirin $x terapeutické užití $7 D001241

650    _2

$a trombocyty $x účinky léků $7 D001792

650    _2

$a studie případů a kontrol $7 D016022

650    12

$a koronární bypass $7 D001026

650    _2

$a nemoci koronárních tepen $x krev $x patologie $x chirurgie $7 D003324

650    _2

$a rozvrh dávkování léků $7 D004334

650    _2

$a monitorování léčiv $x přístrojové vybavení $x metody $7 D016903

650    _2

$a léková rezistence $7 D004351

650    _2

$a ženské pohlaví $7 D005260

650    _2

$a lidé $7 D006801

650    _2

$a mužské pohlaví $7 D008297

650    _2

$a lidé středního věku $7 D008875

650    _2

$a agregace trombocytů $x účinky léků $7 D010974

650    _2

$a inhibitory agregace trombocytů $x terapeutické užití $7 D010975

650    _2

$a vyšetření funkce trombocytů $7 D010979

650    _2

$a thromboxan B2 $x krev $7 D013929

655    _2

$a časopisecké články $7 D016428

700    1_

$a Lakusic, Nenad

700    1_

$a Gaspar, Ludovit

700    1_

$a Kruzliak, Peter

773    0_

$w MED00009346 $t Blood coagulation & fibrinolysis an international journal in haemostasis and thrombosis $x 1473-5733 $g Roč. 27, č. 4 (2016), s. 370-3

856    41

$u https://pubmed.ncbi.nlm.nih.gov/26575493 $y Pubmed

910    __

$a ABA008 $b sig $c sign $y a $z 0

990    __

$a 20170413 $b ABA008

991    __

$a 20170502100853 $b ABA008

999    __

$a ok $b bmc $g 1200687 $s 975000

BAS    __

$a 3

BAS    __

$a PreBMC

BMC    __

$a 2016 $b 27 $c 4 $d 370-3 $i 1473-5733 $m Blood coagulation & fibrinolysis $n Blood Coagul Fibrinolysis $x MED00009346

LZP    __

$a Pubmed-20170413